Europe Human Papillomavirus (HPV) Vaccine Market

The Europe Human Papillomavirus (HPV) Vaccine Market size was valued at US$ 1,202.66 Mn in 2022 and is projected to reach US$ 1,598.81 Mn by 2028, growing at a CAGR of 4.9% during 2022 - 2028.

Report Coverage
  • Type: 9-valent HPV Vaccine, Quadrivalent HPV Vaccine, Bivalent HPV Vaccine
  • Dosage: 2 Dose and 3 Dose
  • Age: 9 to 14 Years and 15 to 45 Years
  • Application: HPV-Attributable Cancer and Genital Warts
  • End User: Doctors Office, Community Health Clinics, School-based Health Centers, Health Departments, Hospitals
US$ 1,202.66 Mn Market size in 2022
US$ 1,598.81 Mn Market Size by 2028
4.9% CAGR, 2022 - 2028
2023-2028 Forecast Period

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Data Triangulation and Validation

4. Europe Human Papillomavirus (HPV) Vaccine Market Landscape

4.1 Overview
4.3 Ecosystem Analysis
  • 4.3.1 List of Vendors in the Value Chain

5. Europe Human Papillomavirus (HPV) Vaccine Market – Key Market Dynamics

5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints

6. Europe Human Papillomavirus (HPV) Vaccine Market Regional Analysis

6.2 Europe Human Papillomavirus (HPV) Vaccine Market Revenue 2020-2028 (US$ Million)
6.3 Europe Human Papillomavirus (HPV) Vaccine Market Forecast Analysis

7. Europe Human Papillomavirus (HPV) Vaccine Market Analysis – by Type

7.1 9-valent HPV Vaccine
  • 7.1.1 Overview
  • 7.1.2 9-valent HPV Vaccine: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)
7.2 Quadrivalent HPV Vaccine
  • 7.2.1 Overview
  • 7.2.2 Quadrivalent HPV Vaccine: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)
7.3 Bivalent HPV Vaccine
  • 7.3.1 Overview
  • 7.3.2 Bivalent HPV Vaccine: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)

8. Europe Human Papillomavirus (HPV) Vaccine Market Analysis – by Dosage

8.1 2 Dose and 3 Dose
  • 8.1.1 Overview
  • 8.1.2 2 Dose and 3 Dose: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)

9. Europe Human Papillomavirus (HPV) Vaccine Market Analysis – by Age

9.1 9 to 14 Years and 15 to 45 Years
  • 9.1.1 Overview
  • 9.1.2 9 to 14 Years and 15 to 45 Years: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)

10. Europe Human Papillomavirus (HPV) Vaccine Market Analysis – by Application

10.1 HPV-Attributable Cancer and Genital Warts
  • 10.1.1 Overview
  • 10.1.2 HPV-Attributable Cancer and Genital Warts: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)

11. Europe Human Papillomavirus (HPV) Vaccine Market – Europe Analysis

11.1 Overview

11.2 Europe
  • 11.2.1 Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Key Country, 2023 and 2028 (%)
  • 11.2.1.1 Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast Analysis – by Country
  • 11.2.1.1 UK: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.1.1 UK: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
    • 11.2.1.1.2 UK: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
    • 11.2.1.1.3 UK: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
    • 11.2.1.1.4 UK: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application
  • 11.2.1.2 Germany: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.2.1 Germany: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
    • 11.2.1.2.2 Germany: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
    • 11.2.1.2.3 Germany: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
    • 11.2.1.2.4 Germany: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application
  • 11.2.1.3 France: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.3.1 France: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
    • 11.2.1.3.2 France: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
    • 11.2.1.3.3 France: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
    • 11.2.1.3.4 France: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application
  • 11.2.1.4 Russia: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.4.1 Russia: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
    • 11.2.1.4.2 Russia: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
    • 11.2.1.4.3 Russia: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
    • 11.2.1.4.4 Russia: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application
  • 11.2.1.5 Italy: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.5.1 Italy: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
    • 11.2.1.5.2 Italy: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
    • 11.2.1.5.3 Italy: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
    • 11.2.1.5.4 Italy: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application
  • 11.2.1.6 Rest of Europe: Europe Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.6.1 Rest of Europe: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
    • 11.2.1.6.2 Rest of Europe: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
    • 11.2.1.6.3 Rest of Europe: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
    • 11.2.1.6.4 Rest of Europe: Europe Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application

12. Competitive Landscape

12.1 Heat Map Analysis
12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments

14. Company Profiles

14.1 2A Pharma
  • 14.1.1 Key Facts
  • 14.1.2 Business Description
  • 14.1.3 Products and Services
  • 14.1.4 Financial Overview
  • 14.1.5 SWOT Analysis
  • 14.1.6 Key Developments
14.2 ChengDu Institute of Biological Products Co., Ltd.
  • 14.2.1 Key Facts
  • 14.2.2 Business Description
  • 14.2.3 Products and Services
  • 14.2.4 Financial Overview
  • 14.2.5 SWOT Analysis
  • 14.2.6 Key Developments
14.3 GlaxoSmithKline plc.
  • 14.3.1 Key Facts
  • 14.3.2 Business Description
  • 14.3.3 Products and Services
  • 14.3.4 Financial Overview
  • 14.3.5 SWOT Analysis
  • 14.3.6 Key Developments
14.4 Inovio Pharmaceuticals
  • 14.4.1 Key Facts
  • 14.4.2 Business Description
  • 14.4.3 Products and Services
  • 14.4.4 Financial Overview
  • 14.4.5 SWOT Analysis
  • 14.4.6 Key Developments
14.5 Merck & Co., Inc.
  • 14.5.1 Key Facts
  • 14.5.2 Business Description
  • 14.5.3 Products and Services
  • 14.5.4 Financial Overview
  • 14.5.5 SWOT Analysis
  • 14.5.6 Key Developments
14.6 R-Pharm
  • 14.6.1 Key Facts
  • 14.6.2 Business Description
  • 14.6.3 Products and Services
  • 14.6.4 Financial Overview
  • 14.6.5 SWOT Analysis
  • 14.6.6 Key Developments
14.7 Sanofi
  • 14.7.1 Key Facts
  • 14.7.2 Business Description
  • 14.7.3 Products and Services
  • 14.7.4 Financial Overview
  • 14.7.5 SWOT Analysis
  • 14.7.6 Key Developments
14.8 Serum Institute of India Pvt. Ltd
  • 14.8.1 Key Facts
  • 14.8.2 Business Description
  • 14.8.3 Products and Services
  • 14.8.4 Financial Overview
  • 14.8.5 SWOT Analysis
  • 14.8.6 Key Developments
14.9 Vaccitech
  • 14.9.1 Key Facts
  • 14.9.2 Business Description
  • 14.9.3 Products and Services
  • 14.9.4 Financial Overview
  • 14.9.5 SWOT Analysis
  • 14.9.6 Key Developments
14.10 Walvax Biotechnology Co., Ltd.
  • 14.10.1 Key Facts
  • 14.10.2 Business Description
  • 14.10.3 Products and Services
  • 14.10.4 Financial Overview
  • 14.10.5 SWOT Analysis
  • 14.10.6 Key Developments

15. Appendix

15.1 About Business Market Insights
15.2 List of Abbreviations

Access the Full E Market Report

Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.

Access the full E Market Report
157 pages PDF & Excel | 2022-10-11